Results 11 to 20 of about 863,493 (265)
Antibody Therapy for Histoplasmosis [PDF]
Frontiers in Microbiology, 2012 The endemic human pathogenic fungus Histoplasma capsulatum is a major fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H.
Nosanchuk, JD +3 more
openaire +4 more sources
Hematology, 2023 Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique +2 more
openaire +3 more sources
Frontiers in Immunology, 2023 The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of cytotoxic lymphocytes.
Sebastian Lutz +19 more
doaj +1 more source
Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
Cells, 2022 Intracerebral hemorrhage (ICH) is recognized as a severe clinical problem lacking effective treatment. High mobility group box-1 (HMGB1) exhibits inflammatory cytokine-like activity once released into the extracellular space from the nuclei.
Dengli Wang +9 more
doaj +1 more source
Frontiers in Oncology, 2021 Angiogenesis is considered one of the hallmarks of cancer and plays a critical role in the development of tumor. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family and participates in excessive cancer cell proliferation and tumor ...
Simin Zhang +11 more
doaj +1 more source
Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors
Xiehe Yixue Zazhi, 2023 In recent years, immunotherapy has become a new method for solid tumor treatment, and a large number of immune preparations have been developed and applied in clinical practice. Among them, immune checkpoint inhibitors (ICIs) are widely used, ushering in
LI Tao +6 more
doaj +1 more source
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
Frontiers in Immunology, 2023 BackgroundDespite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-targeting antibody
Maria Patra-Kneuer +22 more
doaj +1 more source
Microglia-Derived Interleukin 23: A Crucial Cytokine in Alzheimer's Disease?
Frontiers in Neurology, 2021 Neuronal cell death, amyloid β plaque formation and development of neurofibrillary tangles are among the characteristics of Alzheimer's disease (AD). In addition to neurodegeneration, inflammatory processes such as activation of microglia and astrocytes ...
Louisa Nitsch +3 more
doaj +1 more source
Frontiers in Immunology, 2022 Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector function of tumor targeting antibodies, is hampered by ‘Don´t Eat Me!’ signals such as CD47 expressed by cancer cells.
Tobias Zeller +28 more
doaj +1 more source
PRDM14 is overexpressed in chronic pancreatitis prior to pancreatic cancer
FEBS Open Bio, 2018 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal cancer that is typically diagnosed at a later stage with metastases and is difficult to treat.
Chiharu Moriya +2 more
doaj +1 more source